17 results about "Vascular proliferation" patented technology

The invention relates to the field of biological dressings, and discloses an artificial dermis dressing as well as a preparation method and application thereof. The preparation method comprises the following steps: adding water into a container, and freezing until the water is frozen; then adding a collagen A solution, freezing and standing; continuing to add collagen B liquid, freezing and standing; continuing to add collagen A liquid, freezing and then freeze-drying; and cross-linking in a glutaraldehyde solution, and cleaning to obtain the artificial dermis dressing. The dressing provided by the invention can provide a good stent effect and promote cell migration and proliferation, and the healing rate is close to 100% after wound making. In the wound healing process, the dressing can inhibit collagen deposition, relieve inflammatory response, inhibit abnormal hyperplasia of blood vessels, inhibit excessive proliferation of fibroblasts and excessive formation of granulation tissues, and effectively prevent scar formation. The dressing can also effectively inhibit abnormal vascular hyperplasia in a wound area, and fibrosis and scar hyperplasia caused by excessive vascular hyperplasia are prevented.

The invention relates to the field of biological medicines, in particular to an angiogenesis inhibition polypeptide specifically bound with an ITB3 target or pharmaceutically acceptable salt thereof, which is characterized in that the polypeptide is a) or b) or c) as follows: a) a polypeptide shown in any one amino acid sequence in SEQ ID NO: 1-7, b) a polypeptide shown in any one amino acid sequence in SEQ ID NO: 2-7, and c) a polypeptide shown in any one amino acid sequence in SEQ ID NO: 3-7; b) a derivative polypeptide obtained by adding more than one amino acid residue to the amino terminal and / or carboxyl terminal of the polypeptide shown in any one amino acid sequence in SEQ ID NO: 1-7; and c) a derivative polypeptide obtained by adding or replacing more than one amino acid at any site of the polypeptide shown as any one amino acid sequence in SEQ ID NO: 1-7 except the amino terminal and the carboxyl terminal. The angiogenesis inhibiting polypeptide provided by the invention can specifically recognize and bind ITB3, can effectively inhibit angiogenesis, endothelial cell invasion and migration and target transfer in in-vivo and in-vitro experiments, is efficient and low in toxicity, and has potential effects of treating individual tumors, diabetic vascular proliferative diseases, rheumatoid arthritis and neovascular eye diseases.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of a composition in the preparation of a drug for treating diabetic wounds. The composition comprises the following components: *Artemisia capillaris* exosomes, epi-suberol, and 3-hydroxymorinogenone, with a mass ratio of 1:0.1-0.25:0.02-0.05. In this composition, *Artemisia capillaris* exosomes can penetrate the thickened inflammatory exudate layer and glycosylated extracellular matrix of diabetic wounds, reshaping the wound's immune repair microenvironment, promoting fibroblast activation and proliferation, regulating collagen synthesis and deposition, and reducing scar hyperplasia. 3-hydroxymorinogenone can increase vascular endothelial growth factor, promote angiogenesis, and thus promote the repair and healing of diabetic wounds. The synergistic effect of *Artemisia capillaris* exosomes, epi-suberol, and 3-hydroxymorinogenone in this composition significantly shortens the healing cycle of difficult-to-heal diabetic wounds and improves the quality of wound healing.

The invention provides an application of USP7 (ubiquitin-specific protease 7) as a target spot in preparation of drugs for treating vascular abnormal leakage diseases, and relates to the technical field of biomedicine, USP7 (ubiquitin-specific protease 7) as a deubiquitination enzyme not only regulates tumor, nerve and immune related diseases, but also is closely related to vascular endothelial cell functions. In the vascular homeostasis, the USP7 can maintain the integrity of a vascular barrier and inhibit pathological leakage by stabilizing endothelial connexin such as VE-cadherin and beta-catenin; under the inflammation or hypoxia condition, through deubiquitination of HIF-1alpha or NF-kappa B pathway components (such as I kappa B alpha), vascular endothelial cell activation can be promoted, VEGF signal-driven abnormal angiogenesis or release of inflammatory factors can be aggravated, and diabetic retinopathy, tumor vascular hyperplasia and sepsis-related vascular leakage can be participated. According to the application, verification experiments prove that USP7 has a certain protection effect on vascular permeability, and a treatment strategy is provided for vascular abnormal leakage diseases clinically.

The present invention relates to the technical field of medical materials. Provided are a topical cream or patch for scar treatment and a preparation method therefor. The cream or patch is a topical preparation for scar treatment that combines a hormone, an antibiotic and a chemotherapeutic drug. By means of the synergistic effect of the three components, the cream or patch realizes a variety of effects such as sterilization, anti-inflammation, inhibition of fibroblast proliferation and angiogenesis, inhibition of scar hyperplasia, promotion of scar softening, and prevention of infection, thereby improving the efficacy of scar treatment. The preparation can be simply applied topically or used as a patch without injection, which greatly facilitates patient use and achieves the aim of scar prevention and treatment, thereby providing a multi-functional, safe and effective approach for scar treatment.

A compound of Formula (I) is provided: (I) Salts and crystalline forms of the compound of Formula (I) are also provided. The compound of Formula (I) and crystalline forms thereof can be used for the treatment of several conditions linked to the inhibition of SGK-1, such as a cardiovascular disease selected from the group consisting of Long QT syndrome, heart failure, arrhythmia, ischemic injury, ischemic infarction, inflammatory and fibrotic diseases, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, and stent failure; cancer; epilepsy; Parkinson's disease; and Lafora disease.

The invention relates to the technical field of biological medicine, in particular to ureido indolone compounds and a preparation method and application thereof. Compared with the prior art, the ureido indolone compound provided by the invention has the advantages that the activity of VEGFR, PDGFR and / or FGFR can be effectively inhibited, signal transduction of VEGF, PDGF and / or FGF is blocked, and systemic neovascularization (abnormal vascular hyperplasia) related diseases are treated.

Compounds of Formula (1) and Formula (II) are provided:Crystalline forms of the compounds of Formula (1) and Formula (II) are also provided. The compounds of Formula (1) and Formula (II), and crystalline forms thereof can be used for the treatment of several conditions linked to the inhibition of SGK-1, such as a cardiovascular disease selected from the group consisting of Long QT syndrome, heart failure, arrhythmia such as atrial fibrillation, ischemic injury, ischemic infarction, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, and stent failure; cancer; epilepsy; Parkinson's disease; and Lafora disease.

The application discloses a preparation method and application of a multi-morphology fasudil targeted nanomedicine system for diabetes osteoarthritis, and belongs to the technical field of medicines, and comprises the following steps: 1) weighing free fasudil, dissolving the free fasudil in an organic phase solvent, fully stirring and dissolving, and preparing fasudil organic drug stock solution, which is marked as Fas; 2) slowly adding an acid solution to the Fas; the application takes free fasudil as an active drug, constructs Fas@PB-Sr 2+ The composite nano intermediate is subjected to CAP polypeptide targeted modification to obtain multi-morphology targeted nanoparticles. Through a low-temperature hydrothermal process, drug thermal degradation is avoided, square, rod, spherical and porous mesoporous composite morphologies are generated by regulating raw material ratio and reaction conditions, and cartilage specificity enrichment is realized in combination with the CAP polypeptide, multiple pathological damages such as cartilage wear, synovial inflammation and abnormal vascular hyperplasia of diabetes osteoarthritis are improved, joint local drug residence time is prolonged, and systemic drug toxic side effects are reduced.

A maleate salt of the compound of Formula (I) is provided: Crystalline forms of the compound of Formula (I) are also provided. The compound of Formula (I) and crystalline forms thereof can be used for the treatment of several conditions linked to the inhibition of SGK-1, such as a cardiovascular disease selected from the group consisting of Long QT syndrome, heart failure, arrhythmia, atrial fibrillation, ischemic injury, ischemic infarction, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, and stent failure; inflammatory or fibrotic diseases, cancer, epilepsy, Parkinson's disease, and Lafora disease.

The present invention relates to the field of drugs. Specifically, provided are an oligonucleotide targeting IRS-1 mRNA and use thereof in the preparation of a drug for preventing or treating vascular proliferation-related diseases or symptoms. By means of screening a series of antisense oligonucleotide sequences, it is found that when an oligonucleotide sequence contains a contiguous sequence that is substantially the same as GCTGCTGGTG, it has a significant and stable inhibitory effect on IRS-1 expression and angiogenesis under different modification modes. Said oligonucleotide can be used for preventing or treating vascular proliferation-related diseases or symptoms. Said oligonucleotide has broad application prospects.

The invention provides a pharmaceutical composition for adjuvant therapy of breast cancer and application thereof.The pharmaceutical composition comprises morinda citrifolia fermented juice freeze-dried powder, the morinda citrifolia fermented juice freeze-dried powder is prepared through a vacuum freeze-drying technology, and the effective dose of the morinda citrifolia fermented juice freeze-dried powder in adjuvant therapy of breast cancer is 3-12 mg / mL. The combined use of the morinda citrifolia fermented juice and gemcitabine can significantly inhibit the growth of breast cancer cells and vascular hyperplasia, has potential effects of improving chemotherapeutic drugs and reducing side effects of the chemotherapeutic drugs, is helpful to clarify the action mechanism of the morinda citrifolia fermented juice in treating breast cancer and the efficacy of combined chemotherapeutic drugs, and has broad application prospects. The medicinal value of the morinda citrifolia is actually converted into an anti-cancer drug or an auxiliary drug.

A compound of formula (II) is provided: (II) A crystalline form of the compound of formula (II) is provided. The compound of formula (II) and its crystalline form can be used to treat several conditions associated with the inhibition of SGK-1, such as cardiovascular diseases selected from the group consisting of long QT syndrome, heart failure, arrhythmias such as atrial fibrillation, ischemic injury, ischemic infarction, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, and stent failure, cancer, epilepsy, Parkinson's disease, and Lafora's disease. [Formula 1] JPEG2025525475000063.jpg47170

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a double-target compound, a preparation method thereof and application of the double-target compound in preparation of a VEGFR inhibitor and a CA inhibitor. The invention provides a double-target compound which has a structure as shown in a formula I, II, III or IV. The double-target compound provided by the invention has the effects of a VEGFR inhibitor and a CA inhibitor at the same time, and can be used as the VEGFR inhibitor for treating proliferative diseases or symptoms mediated by protein tyrosine kinase; the compound can be used for treating ocular diseases such as ocular pathological neovascular hyperplasia, retinal edema or ischemia and diseases such as malignant tumors and cancers caused by abnormal vascular hyperplasia, and can be used as a CA inhibitor for intraocular pressure rise related diseases and symptoms. The traditional Chinese medicine composition can be used for treating eye diseases such as glaucoma, glaucoma-ciliary cyclitis syndrome, dilation-period cataract and the like, diabetes mellitus, cardiovascular diseases and the like.

The invention provides an anti-CD93 antibody or an antigen binding fragment thereof, and a preparation method and application thereof. The anti-CD93 antibody or the antigen binding fragment thereof can be specifically bound with a CD93 molecule, has strong immunoreactivity on the CD93 molecule, and can effectively block the molecular function of the CD93 molecule by binding with the CD93 molecule, thereby effectively inhibiting tumor growth. Particularly, the invention also provides a humanized anti-CD93 antibody which not only has relatively strong binding capacity to tumor cells expressing CD93 and a good concentration-dependent effect, but also can effectively block the binding of CD93 and a ligand thereof, and can inhibit HUVEC tube formation and tumor growth, so that the humanized anti-CD93 antibody can be used for treating CD93 related diseases (such as angiogenesis diseases and cancers).

To provide compositions and methods for treatment of ocular disease associated with angiogenesis.SOLUTION: The present disclosure provides compositions and methods for the treatment of ocular diseases associated with angiogenesis, particularly wet age-related macular degeneration. Ocular vascular diseases such as age-related macular degeneration and diabetic retinopathy are due to abnormal choroidal or retinal neovascularization respectively. Since the retina consists of well-defined layers of neuronal, glial, and vascular elements, relatively small disturbances such as those seen in vascular proliferation or edema can lead to significant loss of a visual function. Inherited retinal degenerations, such as Retinitis Pigmentosa, are also associated with vascular abnormalities, such as arteriolar narrowing and vascular atrophy.SELECTED DRAWING: None

The application provides a blood vessel proliferation quantification grading method and device, electronic equipment and a storage medium, applied to the technical field of image processing, and provides double-view image data for subsequent steps by acquiring a stereoscopic image of a lesion area; and a three-dimensional point cloud model is constructed by using a parallax map, a corresponding second blood vessel area is obtained by positioning a first blood vessel area recognized in a two-dimensional image to a three-dimensional space, a three-dimensional geometric feature of the blood vessel is extracted by calculating a blood vessel geometric parameter, and necessary parameters are provided for more accurate blood vessel quantification analysis. The three-dimensional density value calculated by using the three-dimensional geometric parameter realizes objective and quantitative grading of the degree of blood vessel proliferation, overcomes the defects of subjectivity and lack of physical distance guidance of the traditional method, and improves the accuracy and reliability of blood vessel proliferation evaluation.